🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareAlcohol metabolism changes on semaglutide — emerging data

Alcohol metabolism changes on semaglutide — emerging data

NeuroNate Thu, Jun 4, 2026 at 10:31 AM 21 replies 364 viewsPage 1 of 5
NeuroNate
Senior Member
2,890
16,789
Dec 2023
Chicago, IL
Jun 4, 2026 at 10:31 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the comparator does most of the work in how this gets reported, and it is not the comparator most people think they are citing.

The bit I cannot resolve on my own is how much of the between-person variation is pharmacokinetic and how much is just adherence measured badly. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8jason_paloalto, Dr.LeslieOBGYN, MikeNYC_runner and 10 others
Reply Quote Save Share Report
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Jun 4, 2026 at 10:34 AM#2
NeuroNate said:
Steady state is the thing most people miss.

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

12 7tyler_CSCS, VanRx_Mike, steve_okc and 9 others
Reply Quote Save Share Report
PharmD_Rodriguez
Senior Member
3,456
14,567
Jan 2024
Miami, FL
Jun 4, 2026 at 10:37 AM#3
NeuroNate said:
Steady state is the thing most people miss.

I will push back on the "any working dose is fine" framing. The maintenance evidence sits overwhelmingly at the top studied dose, and the extension data shows regain tracking dose reduction rather than tracking stopping. Holding low is reasonable; pretending it is evidentially equivalent is not.

11 6robert_kc, dan_philly, MeganSA_TX and 8 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jun 4, 2026 at 10:41 AM#4

Taking the question as asked, rather than the general version of it. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

Last edited: Jun 4, 2026 at 3:41 PM
10 5Dr.PeteFamMed, claudia_zurich, nancy_portland and 7 others
Reply Quote Save Share Report
GraceAZ_72
Member
156
678
Jan 2025
Tucson, AZ
Jun 4, 2026 at 10:59 AM#5
Dr.GutHealth said:
Agreed, though "tolerable" needs defining.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

9 4RetaRick_CA, JenPlateau, SallyK_inj and 6 others
Reply Quote Save Share Report
1235

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register